Source: Fox News
Summary
A trial of 32 bowel cancer patients with a specific genetic profile found that a short course of immunotherapy before surgery resulted in no cancer recurrence in any of the patients after nearly three years. The treatment, which used the drug pembrolizumab, was given for up to nine weeks before surgery and showed promising results, with 59% of patients having no signs of cancer left by the time of surgery. The researchers believe that this approach could be a safe and effective treatment for patients with high-risk bowel cancers.
Our Reading
The advice sounds familiar.
This guidance has been heard before in the context of personalized medicine and targeted therapies. The use of immunotherapy before surgery is a relatively new approach, but the idea of tailoring treatment to individual patients’ genetic profiles is not new. The study’s results are promising, but the researchers acknowledge that the trial was small and had limitations. The use of personalized blood tests to monitor patients is also an interesting development.
The fact that the treatment was able to shrink tumors so effectively that 59% of patients had no signs of cancer left by the time of surgery is a significant finding. The researchers’ optimism about the future of personalized care is also noteworthy.
It’s worth noting that the study’s results are not a guarantee of success, and more research is needed to confirm the effectiveness of this approach. However, the fact that none of the patients have experienced a cancer recurrence after almost three years is a promising sign.
The study’s findings may also have implications for the treatment of other types of cancer.
The researchers’ use of the phrase “personalized care” is a telling one, as it suggests a shift towards more tailored and individualized approaches to treatment.
Author: Evan Null
